New Inhibitors for Breast Cancer Treatment
Author Information
Author(s): Wood Paul M, Woo L W Lawrence, Thomas Mark P, Mahon Mary F, Purohit Atul, Potter Barry V L
Primary Institution: University of Bath
Hypothesis
Concurrent inhibition of aromatase and steroid sulfatase may provide a more effective treatment for hormone-dependent breast cancer than monotherapy against individual enzymes.
Conclusion
The study identified several potent dual inhibitors that could enhance treatment efficacy for hormone-dependent breast cancer.
Supporting Evidence
- Three aromatase inhibitors with sub-nanomolar potency were designed.
- The most potent DASI identified had an IC50 of 0.12 nm.
- Compounds with a para-chloro-substituted ring showed potent aromatase inhibition.
- Lengthening the linker between pharmacophores improved aromatase inhibition.
- Compound 51 is the first sulfamate-containing vorozole derivative.
Takeaway
Scientists are trying to create new medicines that can stop two bad things in breast cancer at once, which might work better than just stopping one.
Methodology
The study involved designing and biologically evaluating new compounds in JEG-3 cells to assess their inhibitory effects on aromatase and steroid sulfatase.
Limitations
The study primarily focused on in vitro evaluations, and further in vivo studies are needed to confirm the efficacy of the compounds.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website